Ayala: Positive Interim Data from Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors

 - Updated interim results from Part A of RINGSIDE show first confirmed partial response (PR) achieved at week 16 and 3 additional unconfirmed PRs over the follow-up period -

- Consistent early tumor shrinkage with measures deepening over time -

- AL102 was well tolerated at all doses evaluated -

- Part B and Open-Label Extension being initiated with the selected dose of 1.2mg once daily -

- Company to host Key Opinion Leader event on September 28 to discuss results -

https://finance.yahoo.com/news/ayala-pharmaceuticals-presents-positive-interim-120000799.html